Medtronic (MDT) — Earnings Preview: Q1 FY27
Key Preview Table: What to Watch for Next Quarter
| Factor | Details & Signals to Watch |
|---|---|
| Revenue Growth | Consensus: $9,548M (+7.6% YoY); Guidance: Q1 organic growth includes ~500–600 bps from extra week |
| Organic Revenue Growth | Guidance: FY27 organic growth 6.75%–7.25% (includes 125 bps from extra week); Q1 guide: 11.5%–12% organic |
| EPS (Non-GAAP) | Guidance: FY27 $5.90–$6.00; Q1 guidance: $1.38–$1.40 |
| Gross Margin | Consensus: 64.8%; Guidance: FY27 gross margin roughly flat ex-tariffs, -20 bps including tariffs |
| Operating Margin | Guidance: FY27 up 60 bps YoY (ex-Blackstone payment/tariffs); Q1 not explicitly guided |
| Tariff Impact | FY27E: $250M headwind, $75M in Q1 |
| Diabetes Business | Still consolidated in guidance; separation timing could provide upside if completed before year-end |
| M&A Dilution | FY27E: 2% EPS dilution from M&A, higher than prior due to earlier deal timing |
| Segment Growth Drivers | CAS (Cardiac Ablation Solutions), Symplicity (RDN), Hugo (robotics), Altaviva (Pelvic Health), Stealth AXiS |
| CAS Revenue | Annualizing at $2B+; expected to remain a major growth driver, with market share gains and new launches |
| Symplicity (RDN) Ramp | Now annualizing at $100M; sequential procedure volume and account growth |
| Hugo Robotics | Early U.S. launch, FDA submissions for new indications; watch for revenue/profit inflection |
| Altaviva | Strong physician training ramp, sequential acceleration in implants |
| Stealth AXiS | Early commercial traction, expected pull-through in CST consumables |
| China | Expected to grow at corporate average, accretive to profitability |
| Currency/FX | FY27E: Neutral to +1% accretive impact assumed |
Summary and Conclusions
- Medtronic enters FY27 with strong momentum: Q4 and FY26 delivered the highest annual revenue growth in a decade (+8.4% reported, +5.8% organic), with Q4 organic growth of +6.6% (90 bps above implied guidance).
- FY27 guidance is robust: Organic revenue growth of 6.75%–7.25% (including 125 bps from an extra selling week), and non-GAAP EPS of $5.90–$6.00 (+6.7% to +8.5% YoY). Q1 organic growth is guided to 11.5%–12% (with 500–600 bps from the extra week); Q1 EPS guided to $1.38–$1.40.
- Key growth drivers: Cardiac Ablation Solutions (CAS) continues to annualize at $2B+ and is expected to contribute similarly to FY27 growth as in FY26. Symplicity (renal denervation) is now annualizing at $100M and ramping. Hugo robotics and Altaviva are both in early-stage commercial ramps, with strong leading indicators.
- Margins: Gross margin is expected to be roughly flat ex-tariffs, with a -20 bps headwind including tariffs. Operating margin is guided up 60 bps YoY, helped by the absence of Blackstone payments and operating leverage.
- M&A and portfolio moves: FY27 guidance includes 2% EPS dilution from M&A, higher than previously expected due to earlier deal closings. Diabetes remains consolidated for now; separation could provide upside if completed before year-end.
- Comparables: FY26 was a strong year, so the company faces a tougher YoY comp, but management expects continued acceleration, especially as new growth drivers scale.
Recent Results: Q4 and FY26 Performance
Q4 FY26 Actuals
| Metric | Q4 FY26 Actual | YoY Growth | Notes |
|---|---|---|---|
| Revenue ($M) | 9,807 | +9.9% | +6.6% organic; 90 bps above guidance |
| Non-GAAP EPS ($) | 1.55 | -4.3% | Above guidance |
| Gross Margin (%) | 65.4 | +30 bps | +50 bps seq.; +30 bps YoY |
| Operating Margin (%) | 25.5 | -230 bps | Includes 160 bps MiniMed/Blackstone, 80 bps tariffs |
| CAS Revenue Growth | +78% | +124% U.S.; gained 8 pts U.S. share | |
| Symplicity (RDN) Run Rate | $100M annual | Doubled avg. weekly procedures post-NCD | |
| Altaviva | +2.5x patients | Nearly 1,000 physicians trained | |
| Hugo Robotics | Early U.S. launch | FDA submissions for new indications |
FY26 Actuals
| Metric | FY26 Actual | YoY Growth | Notes |
|---|---|---|---|
| Revenue ($M) | 36,364 | +8.4% | +5.8% organic |
| Non-GAAP EPS ($) | 5.53 | +0.7% | $0.15 FX benefit; -2.0% constant currency |
| Operating Margin (%) | 24.4 | -130 bps | -150 bps constant currency |
| Free Cash Flow ($M) | 5,426 | +4.6% | 76% FCF conversion |
Forward Consensus vs. Guidance
FY27 Guidance vs. Consensus
| Metric | FY27 Guidance | FY27 Consensus* | Notes |
|---|---|---|---|
| Revenue ($M) | 38,831 | Guidance is for organic growth, not absolute $ | |
| Organic Growth (%) | 6.75–7.25 | ~7.5 | Guidance includes 125 bps from extra week |
| Non-GAAP EPS ($) | 5.90–6.00 | 6.7%–8.5% growth; includes full-year Diabetes, M&A | |
| Gross Margin (%) | Flat ex-tariffs | 65.1 | -20 bps including tariffs |
| Operating Margin (%) | +60 bps YoY | Ex-Blackstone payment/tariffs | |
| Q1 Revenue ($M) | 9,548 | Q1 organic growth guided to 11.5–12% | |
| Q1 Non-GAAP EPS ($) | 1.38–1.40 |
*Consensus figures are not actuals; use for context only.
Segment and Product-Level Dynamics
- CAS (Cardiac Ablation Solutions):
- Annualizing at $2B+; Q4 up +78% globally, +124% U.S.
- Market share now ~15%, with further runway as installed base grew +40% sequentially in Q4.
- New launches: Sphere-9 in Japan, Sphere-360 CE Mark and EU launch, U.S. pivotal trial enrolling.
- Management expects CAS to contribute similarly to FY27 growth as in FY26.
- Symplicity (Renal Denervation):
- Now annualizing at $100M; doubled weekly procedures since NCD.
- Over 300 accounts and 200+ physicians on finder; strong clinical data and reimbursement tailwinds.
- Management expects significant growth in FY27 and beyond.
- Hugo Robotics:
- Early U.S. launch (urology); FDA submissions for general surgery, GYN, LigaSure RAS.
- Touch Surgery digital ecosystem installs up 30% sequentially (now 1,400+ ORs).
- Management expects Hugo to increasingly contribute to MedSurg growth and eventually margins.
- Altaviva (Pelvic Health):
- Nearly 1,000 physicians trained; active implanters up 3x, patients treated up 2.5x sequentially.
- Management expects continued acceleration in FY27.
- Stealth AXiS (CST):
- Early commercial traction; FDA clearance for spine, cranial, ENT; CE Mark for spine/cranial.
- Pull-through expected in CST consumables.
Year-over-Year Comparable
- FY26 was a strong year: +8.4% reported, +5.8% organic revenue growth; highest in a decade.
- Q4 FY26 organic growth: +6.6% (90 bps above implied guidance).
- FY27 faces a tougher comp but management expects further acceleration, driven by scaling growth drivers and new product launches.
- Guidance includes extra week: Adds ~125 bps to full-year growth, 500–600 bps to Q1.
Most Important Factors for Next Quarter
- Execution on Growth Drivers: Watch for continued high growth in CAS, ramp in Symplicity (RDN), Altaviva, and Hugo.
- Margin Progression: Monitor gross margin (flat ex-tariffs), operating margin leverage, and impact of tariffs/M&A dilution.
- Diabetes Separation: Any update on timing—earlier separation could provide upside to EPS.
- M&A Integration: Progress on recent deals (CathWorks, Scientia, SPR Therapeutics, etc.) and their contribution to revenue/EPS.
- China Performance: Expected to grow at corporate average and remain accretive to profitability.
- FX and Macro: Guidance assumes neutral to +1% FX impact; monitor for changes in macro or tariff environment.
Conclusion
Medtronic is entering FY27 with strong momentum, a robust pipeline, and multiple high-growth platforms scaling. The company faces a tougher YoY comp but is guiding to further acceleration, supported by new product launches, tuck-in M&A, and operational discipline. Key areas to watch are the continued ramp of CAS, Symplicity, Hugo, and Altaviva, as well as margin progression and any updates on the Diabetes business separation.
